Does Desloratadine Alter the Serum Levels of Montelukast When Administered in a Fixed-Dose Combination?

Basit Öğe Kaydı
dc.contributor.authorCingi, Cemal
dc.contributor.authorToros, Sema Zer
dc.contributor.authorInce, Iskender
dc.contributor.authorErtugay, Cigdem Kalaycik
dc.contributor.authorGurbuz, M. Kezban
dc.contributor.authorCakli, Hamdi
dc.contributor.authorErdogmus, Nagehan
dc.contributor.authorKarasulu, Ercument
dc.contributor.authorKaya, Ercan
dc.date.accessioned2019-10-27T22:07:23Z
dc.date.available2019-10-27T22:07:23Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives/HypothesisThe aim of this study was to investigate the serum levels of montelukast when administered alone or in combination with desloratadine. Study DesignA prospective crossover study. MethodsTwenty-three healthy volunteers were investigated in two sessions. Volunteers were given 10 mg of montelukast orally with 250 mL water in the first session. The same subjects were given 10 mg of montelukast in fixed combination with 5 mg desloratadine 10 days after first session. Blood samples were collected 2, 3, and 4 hours after drug administration, and kept at -80 degrees C after both applications. Plasma samples were analyzed for montelukast concentration. ResultsMean concentration values of both groups were not statistically different (P>.05), but the differences were statistically significant according to time (P<.05). Statistically significant difference was not found between the groups according to the area under curve on the basis of both marginal and cumulative values for all different time intervals (P>.05). ConclusionsThe absorption rate of montelukast was not altered when administered with desloratadine. This study suggested that desloratadine does not influence the bioavailability of montelukast, and their combination therapy can be used safely.en_US
dc.identifier.doi10.1002/lary.24134en_US
dc.identifier.endpage2614en_US
dc.identifier.issn0023-852X
dc.identifier.issn1531-4995
dc.identifier.issue11en_US
dc.identifier.pmid23918211en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2610en_US
dc.identifier.urihttps://doi.org/10.1002/lary.24134
dc.identifier.urihttps://hdl.handle.net/11454/49005
dc.identifier.volume123en_US
dc.identifier.wosWOS:000326231200017en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofLaryngoscopeen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDesloratadineen_US
dc.subjectmontelukasten_US
dc.subjectfix moleculesen_US
dc.subjectdrug interactionen_US
dc.subjectbioavailabilityen_US
dc.subjectallergyen_US
dc.titleDoes Desloratadine Alter the Serum Levels of Montelukast When Administered in a Fixed-Dose Combination?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu